
Eptokind 50mg/2ml Injection
Marketer
Mankind Pharma Ltd
Salt Composition
Phenytoin (50mg/2ml)
Overview Eptokind 50mg/2ml Injection
Levetiracetam 50mg/2ml injection is indicated for the management and prophylaxis of epilepsy (convulsive episodes). Its mechanism involves suppressing hyperactive neuronal firing in the brain. Parenteral administration is necessary when oral intake is infeasible, such as in inpatient settings. This injection may be employed monotherapeutically or as adjunctive therapy with other anticonvulsants. Dosage and treatment duration should strictly adhere to physician instructions, potentially escalating gradually until seizure control is achieved. Therapeutic efficacy may require several weeks; consistent use is crucial for optimal results. Cessation should only occur under medical guidance; abrupt discontinuation can precipitate increased seizure frequency or exacerbate bipolar symptoms. Commonly reported adverse effects encompass dermatological reactions, cephalalgia, nausea/vomiting, insomnia, vertigo, somnolence, and sedation. While most side effects are transient, persistent or bothersome symptoms warrant medical consultation; mitigating strategies may be available. Prior to initiating treatment, disclose any pre-existing renal or hepatic impairment, meningitis, depressive disorders, or suicidal ideation to your physician. Comprehensive disclosure of all concurrent medications, encompassing oral contraceptives, is also essential due to potential interactions. During pregnancy or lactation, Levetiracetam 50mg/2ml injection can be administered if deemed medically necessary, with potential dosage modifications. Operation of machinery, including driving or cycling, should be avoided if drowsiness or dizziness ensues. Regular blood monitoring may be required to assess therapeutic response.
Uses of Eptokind 50mg/2ml Injection
Managing and mitigating epileptic seizures.
Major Benefits of Eptokind 50mg/2ml Injection:
This medication will be administered by your physician or their designated nurse. Self-medication is strongly discouraged.
Common Side effects of Eptokind 50mg/2ml Injection:
- Rash
- Headache
- Dizziness
- Vomiting
- Nausea
- Slurred speech
- Vertigo
- Confusion
- Nervousness
- Constipation
- Tremors
- Altered walking
How to use Eptokind 50mg/2ml Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
How Eptokind 50mg/2ml Injection works:
Epileptic seizures are managed by the anticonvulsant injection, Eptokind 50mg/2ml, which reduces hyperactive neuronal firing in the brain.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while using Eptokind 50mg/2ml Injection is not advisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Administering Eptokind 50mg/2ml Injection during pregnancy carries a confirmed risk to the fetus. Nevertheless, a physician might exceptionally prescribe it in critical circumstances where the potential advantages outweigh the hazards. Seek medical advice before use.
Breast feedingSAFE IF PRESCRIBED
Eptokind 50mg/2ml injections pose minimal risk during lactation. Research in humans indicates negligible drug transfer to breast milk, posing no known harm to infants. Physician consultation is advised.
DrivingUNSAFE
The administration of Eptokind 50mg/2ml Injection might reduce attentiveness, impair vision, or induce drowsiness and dizziness. Driving should be avoided if any of these effects manifest.
KidneyCAUTION
For individuals with kidney impairment, administration of Eptokind 50mg/2ml Injection requires careful consideration. Dosage modification of Eptokind 50mg/2ml Injection might be necessary. Physician consultation is recommended.
LiverCAUTION
Patients with hepatic impairment should use Eptokind 50mg/2ml Injection cautiously, as dose modification may be necessary. Physician consultation is advised.
What if you forget to take Eptokind 50mg/2ml Injection :
Omit a scheduled Eptokind 50mg/2ml Injection? Seek medical advice.
Facts to Know About Eptokind 50mg/2ml Injection
| Label | Value |
|---|---|
| Chemical Category | Hydantoin-based compound |
| Developing Habits | No. |
| Treatment Category | Neuroscience Central Nervous System |
